Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors

Trial Profile

Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CBP 501 (Primary) ; Cisplatin (Primary) ; Nivolumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Kidney-neoplasms; Liver cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors CanBas
  • Most Recent Events

    • 03 Apr 2019 Results (n=19) as of 28 Dec 2018, assessing safety and tolerability of CBP501 combined with cisplatin and nivolumab in patients colorectal and pancreatic cancer presented at the 110th Annual Meeting of the American Association for Cancer Research
    • 14 Jan 2019 Planned number of patients changed from 42 to 48.
    • 14 Jan 2019 Planned End Date changed from 1 Mar 2019 to 30 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top